Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan:63:103204.
doi: 10.1016/j.ebiom.2020.103204. Epub 2021 Jan 6.

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19

Michael G Ison  1 , Marc H Scheetz  2
Affiliations

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19

Michael G Ison et al. EBioMedicine. 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest MGI receives research support, paid to Northwestern University, from AiCuris, Janssen and Shire. He is a paid consultant for Adagio, AlloVir, Celltrion, Cidara, Genentech/Roche, Janssen, Shionogi and Viracor Eurofins. He is a paid member of DSMBs for Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda and Vitaeris. MHS received research support from Merck and is a paid consultant for Abbvie.

References

    1. McKimm-Breschkin J.L., Jiang S., Hui D.S., Beigel J.H., Govorkova E.A., Lee N. Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antiviral Res. 2018;149:118–142. - PMC - PubMed
    1. Nguyen T.H., Guedj J., Anglaret X. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017;11(2) - PMC - PubMed
    1. Ivashchenko A.A., Dmitriev K.A., Vostokova N.V. AVIFAVIR for Treatment of Patients with Moderate COVID-19: interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2020 - PMC - PubMed
    1. Doi Y., Hibino M., Hase R. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 - PMC - PubMed
    1. Favipiravir Observational Study Group FHU . 2020. Favipiravir observational study interim report 2.http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_favip_e... (accessed 11/8/20)

MeSH terms